Legal and Regulatory Decisions Likely to Drive Biosimilar Approvals in 2017
Will 2017 Change the Fate of Biosimilars? An Update From the CBI Summit
Biosimilar Knowledge Gaps Identified Among US Specialty Physicians
How Will Pfizer's Infliximab Biosimilar Compete With Remicade?
ECCO Supports Switching From Remicade to Biosimilar Infliximab for IBD Patients
EMA Pilot Will Provide Tailored Advice to Biosimilar Developers, Similar to FDA Process
Treating Rheumatoid Arthritis With Biologic Medications: A Quick Take
The FDA vs the EC: Two Very Different Ways to Address Biosimilar Education
EMA Concerns Prompt Sandoz to Withdraw Neulasta Biosimilar Application
What Influences Physicians' Decisions About Patient Suitability for Biosimilar Infliximab?
Three Insulin Makers Face Class-Action Lawsuit on Price Fixing
FDA Filing of Sandoz's Humira Biosimilar Delayed
FDA Hiring Freeze Could Slow Down Biosimilar Approval Process
Novartis: The Company at the Forefront of Biosimilar Development
EMA Committee Recommends Approval of Amgen's Adalimumab Biosimilar
Novartis's Enbrel Biosimilar Marketing Delayed
The Supreme Court: Amgen v. Sandoz Briefing Schedule
Are Biosimilars Potential Market Disruptors?
EMA Launching Pilot to Support Biosimilars Development
FDA Releases Draft Guidance on Biosimilar Interchangeability
Biosimilars for Psoriasis: Spain's Dermatologists Weigh In
Instagram Pages
Here you can access stories featured on our instagram page. Want more biosimilar news? Sign up for our weekly newsletter, delivered to your inbox every Wednesday here.
FDA Extends NDA Review Period for New RA Treatment Expected to Compete with Humira
Biologics Mixing, Diluting, and Repackaging: FDA Draft Guidance
Boehringer Ingelheim Adalimumab Biosimilar Accepted for Review by FDA and EMA
Biogen's Tecfidera Settles Intellectual Patent Dispute
Pfizer Announces Positive Trial Results for Potential Humira Biosimilar
Bristol-Myers Squibb and GeneCentric Diagnostics Exploring Lung Cancer Biomarker Research
Breaking: US Supreme Court to Hear Biosimilars Lawsuits
Which road will the courts take?
What Lies Ahead for the Big Three RA Drugs?
